Outcomes
ADVERSE EVENTS, SECONDARY
The primary efficacy outcome was the proportion of patients with a mRS score of 0 or 1 on day 90 after randomization. The secondary outcomes included the proportion of patients with an mRS score of 2 or less on day 90 after randomization, the proportion of patients with a decrease in NIHSS score of at least 4 points from baseline to day 7 and day 14 after randomization, the proportion of patients with an increase in NIHSS score of 4 or more points, 3 points, 2 points, or 1 point from baseline to day 7 after randomization. Safety outcomes, including adverse events, serious adverse events within 90 days, changes in vital signs, and results of laboratory examinations (routine blood, routine urine, and blood biochemistry examinations) from baseline to day 14 after randomization were systematically recorded.